(firstQuint)An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects.

 This is an open-label, single-dose study in healthy male subjects.

 The study will have 2 phases: Pretreatment and Treatment.

 The Pretreatment Phase will last up to 21 days and will consist of a Screening Period and a Baseline Period, during which each subject's eligibility will be determined and assessments will be conducted.

.

 An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects@highlight

The purpose of this study is to determine the metabolism and excretion of [14C]E2006 in healthy male subjects.

